 Placebo was used as the control during the double-blind treatment period for both delivery methods HFA nasal aerosol and aqueous nasal sprayand for the study outcome analyses. There was also a positive control administered to a subset of these placebo subjects during the last 4 days of Week 6 dexamethasone placebo or dexamethasone 6 mg. The active control was utilized to validate the assay sensitivity ie, distinguish an effective from an ineffective drug of this study, as dexamethasone is a known HPA axis suppressant, therefore this subset of placebo subjects was not included in the study outcome analyses. 